期刊文献+

基于高血压患者报告的临床结局评价量表的计量心理学特征测评 被引量:6

Psychometric assessment of patient-reported outcome scale for hypertension
下载PDF
导出
摘要 目的为考察用于新药临床试验或临床疗效评价的基于高血压患者报告的临床结局评价量表(Hyper-PRO)的科学性,对其计量心理学特征进行评价。方法用Hyper-PRO量表对620例样本(536例高血压患者和84名健康人)进行自评量表式调查,对其信度、效度、反应度和临床可行性等计量心理学特征进行考评。结果分半信度系数:生理领域0.882,心理领域0.924,社会领域0.834,治疗领域0.950,整个量表0.950。克朗巴赫系数:生理领域0.839,心理领域0.905,社会领域0.770,治疗领域0.859,整个量表0.948。内容效度满意。因子分析显示量表的结构效度良好。高血压患者与健康人在每个方面的测评结果比较,除外焦虑和抑郁,其余各方面分量表及总量表得分差异均有统计学意义。结论 Hyper-PRO量表具有较好的信度(分半信度、克朗巴赫系数)、效度(内容效度、结构效度)、反应度和临床可行性,可以作为高血压临床疗效评价研究的工具。 Objective To justify the role of patient-reported outcome scale for hypertension(Hyper-PRO) in clinical trials of new drug development,and to evaluate its psychometric characteristics.Methods A total of 620 subjects(536 with hypertension and 84 healthy individuals) received outcome scale interview using Hyper-PRO.Psychometric characteristics,for instance,reliability,validity,responsiveness and clinical feasibility,were evaluated.Results Split-half reliability was 0.882,0.924,0.834,0.950 and 0.950 in physiological,psychological,social,treatment dimension and the whole scale,respectively.While the Cronbach′s coefficient was 0.839,0.905,0.770,0.859 and 0.948 in physiological,psychological,social,treatment dimension and the whole scale,respectively.Content validity was satisfied,and factor analysis showed preferable construct validity.Statistically significant difference was revealed in each dimension between patients with hypertension and normal individuals(P0.05),with the exception of anxiety and depression scores.Conclusion With preferable reliability(split-half reliability and Cronbach′s coefficient),validity(content and structure),responsiveness as well as clinical feasibility,Hyper-PRO scale can be the tool for clinical assessment of hypertension.
出处 《中国药物与临床》 CAS 2012年第1期12-15,共4页 Chinese Remedies & Clinics
基金 山西省科技基础条件平台建设项目(010091018)
关键词 高血压 结果评价(卫生保健) 计量心理学测评 Hypertension Outcome assessment(Health care) Assessment of psychometrics
  • 相关文献

参考文献5

  • 1刘凤斌.中医临床疗效评价量表实施设想[N].中国中医药报,2003-03-17.
  • 2FDA.Guidance for industry-patient-reported outcome measures:use in medical product development to support labeling claims,draft guidance.Health Qual Life,2006,4:79.
  • 3Power M,Quinn K,Schmidt S,et al.Development of the WHO-QOL-old module.Qual Life Res,2005,14(10):2197-2214.
  • 4Laidlaw K,Power MJ,Schmidt S,et al.The at-titudes to ageing questionnaire(AAQ):development and psy-chometric properties.Int J Geriatr Psychiatry,2007,22(4):367-379.
  • 5Marchesini G,Bianchi G,Amodio P,et al.Factors associated with poor health-related quality of life of patients with cirrhosis.Gas-troenterol,2001,120(1):170-178.

共引文献6

同被引文献46

引证文献6

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部